Cargando…
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies
Background: The usefulness of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) for the assessment of idiopathic inflammatory myopathies (IIMs) is acknowledged, but laboratory standardization remains a challenge. We detected MSAs/MAAs by multi-analytic line immuno...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572214/ https://www.ncbi.nlm.nih.gov/pubmed/37835823 http://dx.doi.org/10.3390/diagnostics13193080 |
_version_ | 1785120182547513344 |
---|---|
author | Ghirardello, Anna Gatto, Mariele Franco, Chiara Zanatta, Elisabetta Padoan, Roberto Ienna, Luana Gallo, Nicoletta Zen, Margherita Lundberg, Ingrid E. Mahler, Michael Doria, Andrea Iaccarino, Luca |
author_facet | Ghirardello, Anna Gatto, Mariele Franco, Chiara Zanatta, Elisabetta Padoan, Roberto Ienna, Luana Gallo, Nicoletta Zen, Margherita Lundberg, Ingrid E. Mahler, Michael Doria, Andrea Iaccarino, Luca |
author_sort | Ghirardello, Anna |
collection | PubMed |
description | Background: The usefulness of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) for the assessment of idiopathic inflammatory myopathies (IIMs) is acknowledged, but laboratory standardization remains a challenge. We detected MSAs/MAAs by multi-analytic line immunoassay (LIA) and particle-based multi-analyte technology (PMAT) in a multicenter cohort of patients with IIMs. Methods: We tested the sera from 411 patients affected with definite IIM, including 142 polymyositis (PM), 147 dermatomyositis (DM), 19 cancer-associated myositis, and 103 overlap myositis syndrome (OM), and from 269 controls. MSAs/MAAs were determined by 16Ags LIA in all sera, and anti-HMGCR by ELISA in 157/411 IIM sera and 91/269 control sera. The analytical specificity of LIA/HMGCR ELISA was compared with that of PMAT in 89 MSA+ IIM sera. Results: MSAs/MAAs were positive in 307/411 (75%) IIM patients and 65/269 (24%) controls by LIA (Odds Ratio 9.26, 95% CI 6.43–13.13, p < 0.0001). The sensitivity/specificity of individual MSAs/MAAs were: 20%/100% (Jo-1), 3%/99.3% (PL-7), 4%/98.8% (PL-12), 1%/100% (EJ), 0.7%/100% (OJ), 9%/98% (SRP), 5.6%/99.6% (TIF1γ), 4.6%/99.6% (MDA5), 8%/96% (Mi-2), 1.5%/98% (NXP2), 1.7%/100% (SAE1), 4%/92% (Ku), 8.5%/99% (PM/Scl-100), 8%/96% (PM/Scl-75), and 25.5%/79% (Ro52). Anti-HMGCR was found in 8/157 (5%) IIM patients and 0/176 (0%) controls by ELISA (p = 0.007). Concordance between LIA/HMGCR ELISA and PMAT was found in 78/89 (88%) samples. Individual MSAs detected by LIA were associated with IIM subsets: Jo-1 with PM and OM, PL-12 with OM, Mi-2, TIF1γ, and MDA5 with DM, SRP with PM, and PM/Scl-75/100 with OM (p < 0.001 for all). Conclusions: Since MSAs are mostly mutually exclusive, multi-specific antibody profiling seems effective for a targeted clinical-serologic approach to the diagnosis of IIMs. |
format | Online Article Text |
id | pubmed-10572214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105722142023-10-14 Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies Ghirardello, Anna Gatto, Mariele Franco, Chiara Zanatta, Elisabetta Padoan, Roberto Ienna, Luana Gallo, Nicoletta Zen, Margherita Lundberg, Ingrid E. Mahler, Michael Doria, Andrea Iaccarino, Luca Diagnostics (Basel) Article Background: The usefulness of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) for the assessment of idiopathic inflammatory myopathies (IIMs) is acknowledged, but laboratory standardization remains a challenge. We detected MSAs/MAAs by multi-analytic line immunoassay (LIA) and particle-based multi-analyte technology (PMAT) in a multicenter cohort of patients with IIMs. Methods: We tested the sera from 411 patients affected with definite IIM, including 142 polymyositis (PM), 147 dermatomyositis (DM), 19 cancer-associated myositis, and 103 overlap myositis syndrome (OM), and from 269 controls. MSAs/MAAs were determined by 16Ags LIA in all sera, and anti-HMGCR by ELISA in 157/411 IIM sera and 91/269 control sera. The analytical specificity of LIA/HMGCR ELISA was compared with that of PMAT in 89 MSA+ IIM sera. Results: MSAs/MAAs were positive in 307/411 (75%) IIM patients and 65/269 (24%) controls by LIA (Odds Ratio 9.26, 95% CI 6.43–13.13, p < 0.0001). The sensitivity/specificity of individual MSAs/MAAs were: 20%/100% (Jo-1), 3%/99.3% (PL-7), 4%/98.8% (PL-12), 1%/100% (EJ), 0.7%/100% (OJ), 9%/98% (SRP), 5.6%/99.6% (TIF1γ), 4.6%/99.6% (MDA5), 8%/96% (Mi-2), 1.5%/98% (NXP2), 1.7%/100% (SAE1), 4%/92% (Ku), 8.5%/99% (PM/Scl-100), 8%/96% (PM/Scl-75), and 25.5%/79% (Ro52). Anti-HMGCR was found in 8/157 (5%) IIM patients and 0/176 (0%) controls by ELISA (p = 0.007). Concordance between LIA/HMGCR ELISA and PMAT was found in 78/89 (88%) samples. Individual MSAs detected by LIA were associated with IIM subsets: Jo-1 with PM and OM, PL-12 with OM, Mi-2, TIF1γ, and MDA5 with DM, SRP with PM, and PM/Scl-75/100 with OM (p < 0.001 for all). Conclusions: Since MSAs are mostly mutually exclusive, multi-specific antibody profiling seems effective for a targeted clinical-serologic approach to the diagnosis of IIMs. MDPI 2023-09-28 /pmc/articles/PMC10572214/ /pubmed/37835823 http://dx.doi.org/10.3390/diagnostics13193080 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ghirardello, Anna Gatto, Mariele Franco, Chiara Zanatta, Elisabetta Padoan, Roberto Ienna, Luana Gallo, Nicoletta Zen, Margherita Lundberg, Ingrid E. Mahler, Michael Doria, Andrea Iaccarino, Luca Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies |
title | Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies |
title_full | Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies |
title_fullStr | Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies |
title_full_unstemmed | Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies |
title_short | Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies |
title_sort | detection of myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572214/ https://www.ncbi.nlm.nih.gov/pubmed/37835823 http://dx.doi.org/10.3390/diagnostics13193080 |
work_keys_str_mv | AT ghirardelloanna detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT gattomariele detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT francochiara detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT zanattaelisabetta detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT padoanroberto detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT iennaluana detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT gallonicoletta detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT zenmargherita detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT lundbergingride detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT mahlermichael detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT doriaandrea detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies AT iaccarinoluca detectionofmyositisautoantibodiesbymultianalyticimmunoassaysinalargemulticentercohortofpatientswithdefiniteidiopathicinflammatorymyopathies |